Dr. Lal PathLabs Limited (BOM:539524)
India · Delayed Price · Currency is INR 1,599.75
-18.35 (-1.13%)
At close: May 29, 2026
Dr. Lal PathLabs Revenue
In the fiscal year ending March 31, 2026, Dr. Lal PathLabs had annual revenue of 27.63B INR with 12.25% growth. Dr. Lal PathLabs had revenue of 7.03B in the quarter ending March 31, 2026, with 16.61% growth.
Revenue
27.63B
Revenue Growth
+12.25%
P/S Ratio
9.73
Revenue / Employee
5.55M
Employees
4,980
Market Cap
268.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 27.63B | 3.02B | 12.25% |
| Mar 31, 2025 | 24.61B | 2.35B | 10.54% |
| Mar 31, 2024 | 22.27B | 2.10B | 10.40% |
| Mar 31, 2023 | 20.17B | -705.26M | -3.38% |
| Mar 31, 2022 | 20.87B | 5.06B | 32.01% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Thyrocare Technologies | 8.29B |
| One Global Service Provider | 4.99B |
| Chandan Healthcare | 2.65B |
| Star Imaging and Path Lab | 885.27M |
| Modern Diagnostic & Research Centre | 814.48M |
| Invicta Diagnostic | 330.42M |
| Aspira Pathlab & Diagnostics | 249.82M |
| Clinitech Laboratory | 96.79M |
Dr. Lal PathLabs News
- 4 weeks ago - Dr. Lal PathLabs Earnings Call Transcript: Q4 2026 - Transcripts
- 4 weeks ago - Dr. Lal PathLabs Quarterly report: Q4 2026 - Filings
- 4 weeks ago - Dr. Lal PathLabs Slides: Q4 2026 - Filings
- 4 weeks ago - Dr Lal PathLabs records Rs 703 Cr revenue with 16.6% growth in Q4 FY26 - Business Upturn
- 4 weeks ago - Dr Lal Pathlabs Q4 Results: Profit falls 15% as margin declines nearly 300 bps - Business Upturn
- 4 weeks ago - Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Q4 2026: Everything You Need to Know Ahead of Earnings - GuruFocus
- 2 months ago - Petronet LNG, HDFC Bank & more: Top stocks to watch today - The Times of India
- 4 months ago - Dr Lal PathLabs share in focus as CLSA sees ~17% upside on volume-led growth - Business Upturn